Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$12.47M-15.5%$14.76M-8.1%$16.05M-19.5%$19.95M-6.4%$21.32M-10.4%
-$128.58M+76.5%-$546.38M-8.0%-$506.01M+4.3%-$528.73M+19.9%-$660.12M-111%
-$119.15M+30.5%-$171.43M+38.2%-$277.32M+6.0%-$294.95M+29.7%-$419.27M+3.2%
-$133.28M+75.9%-$553.86M+16.8%-$665.69M+3.6%-$690.89M+15.9%-$821.89M-73.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Pacific Biosciences of California's revenue?
Pacific Biosciences of California (PACB) generated $160.0M in revenue over the trailing twelve months, up 5.0% year over year.
Is Pacific Biosciences of California profitable?
Pacific Biosciences of California is not currently profitable: it reported a net loss of $128.6M over the trailing twelve months, a -80.3% net margin.
What are Pacific Biosciences of California's profit margins?
Gross margin is 37.5% and operating margin is -83.3%, with a -80.3% net margin.
What is Pacific Biosciences of California's earnings per share?
Pacific Biosciences of California's diluted EPS over the trailing twelve months is $-0.43.
Where does Pacific Biosciences of California's income statement data come from?
Every line is extracted from Pacific Biosciences of California's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.